The Scientist Discusses Cancer Commons in Self-Tracking Article

Reporter Kerry Grens mentions Cancer Commons in a recent article in The Scientist. The piece explores the trend of self-tracking—monitoring one’s health over time using a variety of cutting-edge and traditional procedures, including genotyping, gut microbiome sequencing, hormone level measurement, heart rate variability tracking, weight measurement, and more. From the article:

“To further research, organizations have tapped into people’s interest in sharing personal data. Cancer Commons, a large network of cancer researchers, appeals to patients and their physicians to submit individual data on treatment, cancer genotype, and outcomes.”

Read the full article here.


Forbes Covers Cancer Commons

Paul Howard writes about Cancer Commons in the new Forbes blog post “Can We Build a Kickstarter for Cancer?” From the post:

“The Cancer Commons approach – a distributed framework for empowering patients and learning from every patient/treatment combination – breaks down traditional distinctions between clinical trials and patient treatment in the “real world.” Instead of developing treatments in a lab and then testing them on randomized patients in clinical trials (designed to benefit future patients), researchers would apply the latest scientific knowledge and tools to help each patient achieve the best possible outcome today based on what we know – or think we can predict – about a molecular subtype of cancer.”

Read more here.


Cancer Commons in The Journal of Oncopathology

Cancer Commons is mentioned in a recently-published paper in The Journal of Oncopathology. In Crowdsourcing for Science and Medicine: Progress and Challenges, Sheryl Torr-Brown, PhD, writes:

“Another open source data collection effort to improve patient care is Cancer Commons, a nonprofit science initiative, comprised of an elite group of volunteer physicians and scientists, who collect patient data and make it broadly accessible for analysis. The initiative has already published a molecular disease model for lung cancer that is online and widely accessible.”

Read the paper here.


Nature Biotechnology Publishes Cancer Megafund Article by Marty Tenenbaum

On June 10, the journal Nature Biotechnology published an article written by Cancer Commons founder Marty Tenenbaum. The piece addresses a previously published article that proposes a megafund approach to finance biomedical research. According to Dr. Tenenenbaum, the megafund approach will not only reduce risk for investors, but will also “slash the time, cost and risk of drug development by radically rethinking development processes, business models and organizational structures, and requiring the open sharing of data, knowledge and resources across portfolio projects. The resulting impact on productivity, risk and new therapeutic opportunities could potentially dwarf the returns from financial engineering.”

Read Dr. Tenenbaum’s article here: The Cancer Megafund: A Catalyst for Disruptive Innovation. Nature Biotechnology 31, 491-492 (2013) doi:10.1038/nbt.2605.


Watch and Read: Dr. Tenenbaum on The Impact of Personalized Medicine

On May 7, Cancer Commons founder Marty Tenenbaum hosted a panel in The Scientists three-part webinar series Decoding DNA: New Twists and Turns. A summary of the webinar was featured in the June issue of The ScientistThe Scientist June 2013 JMT Webinar. Watch Dr. Tenenbaum and other experts discuss The Impact of Personalized Medicine:

The Impact of Personalized Medicine from thescientistllc on Vimeo:

“After the human genome was sequenced, Personalized Medicine became an end goal, driving both academia and the pharma/biotech industry to find and target cellular pathways and drug therapies that are unique to an individual patient. The final webinar in the series will help us better understand The Impact of Personalized Medicine, what we can expect to gain and where we stand to lose.

Panelists:

Jay M. (‘Marty’) Tenenbaum, Ph.D., Chairman and Founder, Cancer Commons

Amy P. Abernethy, M.D., Associate Professor of Medicine, Duke University School of Medicine and Director of the Duke Cancer Care Research Program

Geoffrey S. Ginsburg, MD, PhD, Director, Genomic Medicine, Duke Institute for Genome Sciences & Policy Executive Director, Center for Personalized Medicine Duke Medicine, Professor of Medicine and Pathology Duke University Medical Center

Abhijit ‘Ron’ Mazumder, Ph.D., Global Head, Research & Product Development, Janssen Diagnostics, Janssen Pharmaceutical companies of Johnson and Johnson”

 


Dr. Tenenbaum to Speak as Panel Host for The Scientist Magazine's Webinar Series

On Tuesday, May 7, Dr. Tenenbaum will host a panel in The Scientists three-part webinar series Decoding DNA: New Twists and Turns. The series, which began on April 18, takes “a bold look at what the future holds for DNA research, bringing together senior investigators and key leaders in the field of genetics and genomics.” Dr. Tenenbaum will speak during the final webinar, The Impact of Personalized Medicine.

From The Scientist‘s description:

“After the human genome was sequenced, Personalized Medicine became an end goal, driving both academia and the pharma/biotech industry to find and target cellular pathways and drug therapies that are unique to an individual patient. The final webinar in the series will help us better understand The Impact of Personalized Medicine, what we can expect to gain and where we stand to lose.”

Dr. Tenenbaum will be joined by Amy P. Abernethy, M.D., Associate Professor of Medicine, Duke University School of Medicine and Director of the Duke Cancer Care Research Program; and Abhijit “Ron” Mazumder, Ph.D., Global Head, Research & Product Development, Janssen Diagnostics, Janssen Pharmaceutical companies of Johnson and Johnson.

When: Tuesday, May 7, 2013, 2:30–4:00 pm ET. Register here.


Smart Patients Launches Online Community for Cancer Patients and Caregivers

Cancer Commons’ partner Smart Patients launched publicly today after a presentation at the TEDMED conference in Washington, DC. Smart Patients is an online discussion platform for cancer patients and their caregivers that will enable them to learn from each other and improve their care. The free website lets users share insights about personal treatment experiences, discuss breaking science, and search for clinical trials, as shown in this demo video:

 

 

Cancer Commons will be partnering with Smart Patients to bring patients’ insights to our Rapid Learning Communities. Cancer Commons’ research collaborators will be able to access anonymous insights from Smart Patients discussions. These insights will help Cancer Commons in its mission to make sure every cancer patient is treated according to what’s working best for similar patients.

Read more at our Need to Know blog or visit www.smartpatients.com.


Cancer Commons and the $10 Million Prostate Cancer Dream Team

A multicenter “dream team” of scientists, led by the University of California, San Francisco (UCSF), has embarked on a groundbreaking $10M initiative in personalized medicine, to overcome therapeutic resistance in patients with advanced prostate cancer. The grant is provided by Stand Up To Cancer and the Prostate Cancer Foundation.

Continue reading…


Cancer Commons Featured in The Scientist Magazine

Do-It-Yourself-Medicine: Patients are sidestepping clinical research and using themselves as guinea pigs to test new treatments for fatal diseases. Will they hurt themselves, or science?

From the article by Jeff Akst:

“When you have gigabytes of data, perhaps hundreds of gigabytes, for each patient, that’s more data than has existed in all clinical trials combined up until a couple of years ago,” says Marty Tenenbaum, who in 2010 founded Cancer Commons, a database that collates real-time patient data and up-to-the-moment basic medical research to inform cancer treatment.

See the full article here.